Catalent Capabilities Update March 2026: Analytical Services

Luke Dieters, Head of Biologics Analytical Services at Catalent’s Kansas City facility, presents an overview of the company’s biologics analytical capabilities. He explains Catalent’s three core divisions and highlights the biologics segment’s role in supporting drug development from early discovery through commercial stages. The Kansas City site serves as a center of excellence, with over 30 years of experience, hundreds of supported programs, and strong regulatory compliance.

Dieters emphasizes Catalent’s patient-first approach, robust quality standards, and high client satisfaction. He outlines services including developability assessments, formulation development, analytical method development and validation, and extensive molecular characterization. The facility supports diverse modalities such as antibodies, gene therapies, conjugates, and nucleic acids.

Advanced bioassay, molecular biology, and stability testing capabilities further strengthen its offerings. With integrated and standalone solutions, Catalent provides comprehensive analytical support to help bring biologic therapies efficiently from concept to market.